Individual License: $2,950 | Team and Enterprise License Options Available

The global Oncology Imaging AI market is forecast to grow from US$604.7M in 2023 to US$7.74B by 2032 (32.7% CAGR)—making oncology one of the fastest-scaling categories inside medical imaging AI and a leading indicator for where enterprise buyers will place their next AI budgets.

Overview

Global Oncology Imaging AI Market Pulse 2025–2032: Size, Mix & Momentum is Marketstrat’s world-market sizing and forecasting report for AI in cancer imaging—covering how demand is shifting across regions, modalities (CT, mammography/DBT, MRI, PET/Nuclear, ultrasound), clinical applications, tumor sites, care pathway stages, end-use settings, and revenue models.

This Pulse is built for teams who want a clean, quantitative global view—without needing to navigate a full multi-hundred-page Horizon program. It delivers a fast, decision-grade answer to:

• How big is the global oncology imaging AI market today—and where will it be by 2032?
• Where is the mix of spend concentrated (the “big pools”)?
• Where will incremental dollars accrue (the “fast pools” and “growth contribution” lanes)?
• How do monetization models shift (software vs services vs cloud/usage-based)?

Market expands from US$604.7M (2023) to US$7.74B (2032) at a 32.7% CAGR, driven primarily by attach-rate expansion and workflow adoption, not scanner unit growth.

Key Market Trends (what’s changing)

1. From “point AI” to pathway adoption
   Oncology imaging AI is shifting from single-task CAD toward pathway-wide workflows—screening, detection, staging, treatment planning (including RT), response assessment, and surveillance—where standardized measurement becomes a clinical and economic requirement.

2. Screening programs anchor predictable AI volumes
   Breast screening (mammography/DBT) and LDCT lung screening continue to expand and industrialize, increasing demand for AI that supports triage, QA, second reads, and program operations at scale.

3. Measurement-grade quantification becomes the value center
   Across MRI (prostate/liver), CT (lung pathways), and PET/Nuclear (theranostics), growth increasingly concentrates in quantification, analytics, and structured reporting—tools that make cancer imaging more reproducible and operationally scalable.

4. Premium pools rise in MRI and PET/Nuclear (high ARPU lanes)
   MRI is the fastest-growing major modality, and PET/Nuclear grows as a high-value niche as therapy-linked imaging (including theranostics) expands demand for quantification and dosimetry-oriented AI.

5. Monetization shifts toward software + usage + lifecycle services
   Software remains the core revenue engine, while cloud/usage-based (PPU) models accelerate in high-volume workflows (screening hubs, teleradiology, and enterprise multi-site networks). Services expand alongside validation, monitoring, and governance requirements.

Competitive Snapshot (commercial reality, not market shares)

This Global Pulse focuses on how the market is captured—not vendor-by-vendor market shares. The report highlights the commercial rails that shape winners and pricing power across segments:

• OEM bundling and “default attach” economics in high-volume modalities and screening lanes
• Enterprise contracting and governance requirements in IDNs and cancer networks
• Marketplace/platform distribution that reduces deployment friction for multi-vendor portfolios
• Teleradiology and centralized reading hubs as catalysts for usage-based pricing and standardized QA

The following companies/divisions have been mentioned (not profiled): Aidoc; AIQ Solutions; Annalise.ai; Arterys; Bayer; Blackford; Calantic; Canon Medical; CARPL.ai; DeepHealth; Deepwise; Densitas; EXINI Diagnostics; Fujifilm; GE HealthCare; Hermes Medical Solutions; Hologic; Imbio; Incepto; Kheiron; Koios Medical; Lantheus; Lunit; Median Technologies; MIM Software; Mindray; Mirada Medical; MVision AI; Nuance; Oxipit; Perspectum; Philips; Ping An Healthcare; Quibim; Qure.ai; Rad AI; RadNet; RaySearch; Riverain; ScreenPoint; Sectra; Segami; Siemens Healthineers; Subtle Medical; Tempus; TheraPanacea; United Imaging; Vara; Varian

If you need deeper strategy frameworks, cluster scorecards, and competitive playbooks, this Pulse pairs naturally with the companion Oncology Imaging AI Strategy Pulse.

Sample Insights & Figures (what you’ll be able to cite)

Inside this report, readers gain immediate answers to questions such as:

• Which regions are over- or under-indexed in specific modalities or pathway stages versus the global mix?
• Where is the largest dollar lift coming from—by modality, tumor site, pathway stage, and revenue stream?
• Which tumor-site × modality combinations create the most incremental dollars (e.g., breast × X-ray/DR, lung × CT, prostate × MRI)?
• Where are cloud/PPU models structurally advantaged versus traditional licensing?

This Pulse includes 41 figures and 36 tables, structured to be reusable in planning decks, investment briefs, and GTM prioritization.

What’s Inside

• Executive Summary focused on global size, growth, and the few mix shifts that matter most
• Condensed Research Methodology (scope definition, segmentation compass, and forecast architecture)
• World Market Analysis (2023–2032) across:
  • Region and selected country views
  • Modality mix and growth contribution
  • Clinical application mix and momentum
  • Tumor-site mix and growth contribution
  • Revenue streams (hardware, software, services, cloud/PPU)
  • End-use organizations (IDNs/AMCs, cancer centers, community providers, teleradiology)
  • Pathway stage dynamics (screening → treatment planning/RT → response/surveillance)
  • Mix & Momentum matrices and cross-tabs (e.g., region × modality, tumor site × modality, pathway stage × revenue stream)

Why This Report

Global Oncology Imaging AI Market Pulse 2025–2032 is built for teams that need high-confidence sizing plus practical segmentation—the combination required to make real decisions:

• Portfolio and roadmap decisions: Which modalities and tumor sites are worth sustained investment?
• Market entry and sequencing: Where do you start (big pools) vs where do you place selective bets (fast pools)?
• Commercial strategy: How will revenue models evolve (license vs service vs usage), and where will pricing compress vs hold?
• Investor and diligence workflows: Which growth narratives are supported by global mix/momentum patterns rather than anecdote?

For a deeper, end-to-end view of the Oncology Imaging AI market—including full regional and country chapters, strategic frameworks, and the complete segmentation model—please see Marketstrat’s World Market for Oncology Imaging AI 2025–2032 (Horizon Report).

Report Stats

• No. of Pages: 111
• No. of Figures: 30
• Companies/Divisions Mentioned (not profiled): ~45
• Price: Individual License: $2,950 | Team License: $3,450 | Enterprise License $3,950
• SKU: MINTP-M01119-2